Dengue vaccine

src: static.straitstimes.com.sg

Dengue vaccine is a vaccine to prevent dengue fever in humans. The World Health Organization only recommends the vaccine as a possible option in areas of the world where the disease is common. In 2017 the manufacturer recommended that the vaccine only be used in people who have previously had a dengue infection, as outcomes may be worsened in those who have not been previously infected. This has caused a scandal in the Philippines where more than 733,000 children were vaccined.

The development of vaccine for dengue fever began as early as 1929, but has been hindered first by incomplete knowledge of the disease pathogenesis, and later by the need to simultaneously create a stable immunity against all four dengue serotypes. Several vaccine candidates are in development including live attenuated, inactivated, DNA and subunit vaccines. Live attenuated vaccine candidates are the furthest along in development.

In 2016 a partially effective vaccine for dengue fever (Dengvaxia) became commercially available in 11 countries: Mexico, the Philippines, Indonesia, Brazil, El Salvador, Costa Rica, Paraguay, Guatamala, Peru, Thailand, and Singapore. In Indonesia it costs about US$207 for the recommended three doses. WHO recommends that use be limited to areas where the disease is common because vaccination may actually increase the risk of dengue fever in people who have not been previously infected with the dengue virus because of the phenonmenon of antibody-dependent enhancement.

Video Dengue vaccine

CYD-TDV

CYD-TDV, sold under the brand name Dengvaxia and made by Sanofi Pasteur , is a live attenuated tetravalent chimeric vaccine made using recombinant DNA technology by replacing the PrM (pre-membrane) and E (envelope) structural genes of the yellow fever attenuated 17D strain vaccine with those from four of the five dengue serotypes. In 2017 the manufacturer recommended that the vaccine only be used in people who have previously had a dengue infection as otherwise there was evidence it may worsen subsequent infections. The initial protocol did not require baseline blood samples prior to vaccination in order to establish an understanding of increased risk of severe dengue in participants who had not been previously exposed. In November 2017 Sanofi acknowledged that some participants were put at risk of severe dengue if they had no prior exposure to the infection; subsequently the Philippines government suspended the mass immunization program with the backing of the WHO which began a review of the safety data.

Ongoing phase III trials in Latin America and Asia involve over 31,000 children between the ages of 2 and 14 years. In the first reports from the trials, vaccine efficacy was 56.5% in the Asian study and 64.7% in the Latin American study in patients who received at least one injection of the vaccine. Efficacy varied by serotype. In both trials vaccine reduced by about 80% the number of severe dengue cases. An analysis of both the Latin American and Asian studies at the 3rd year of follow-up showed that the efficacy of the vaccine was 65.6% in preventing hospitalization in children older than 9 years of age, but considerably greater (81.9%) for children who were seropositive (indicating previous dengue infection) at baseline. The vaccination series consists of three injections at 0, 6 and 12 months. The vaccine was approved in Mexico, Philippines, and Brazil in December 2015, and in El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Indonesia, Thailand and Singapore in 2016. Tradenamed Dengvaxia, it is approved for use for those aged nine and older and can prevent all four serotypes.

Maps Dengue vaccine

DENVax

DENVax is a recombinant chimeric vaccine with DENV1, DENV3, and DENV4 components on a dengue virus type 2 (DENV2) backbone originally developed at Mahidol University in Bangkok and now funded by Inviragen and Takeda. Phase I and II trials are ongoing in the United States, Colombia, Puerto Rico, Singapore and Thailand.

src: business.inquirer.net

TetraVax-DV

TetraVax-DV is a tetravalent admixture of monovalent vaccines that were tested separately for safety and immunogenicity. The vaccine passed phase I trials and is being tested in phase II studies in Thailand and Brazil. In Brazil, the studies are being done in collaboration with the Instituto Butantan.

src: assets.rappler.com

TDENV PIV

TDEN PIV is inactivated tetravalent vaccine undergoing phase I trials as part of a collaboration between GSK and the Walter Reed Army Institute of Research. A synergistic formulation with another live attenuated candidate vaccine (prime-boost strategy) is also being evaluated in a phase II study. In prime-boosting, one type of vaccine is followed by a boost with another type in an attempt to improve immunogenicity.

src: thumbs.dreamstime.com

V180

Merck is studying recombinant subunit vaccines expressed in Drosophila cells. Studies are in phase I stage as of 2015.

src: 1.bp.blogspot.com

DNA vaccines

The Naval Medical Research Center attempted to develop a monovalent DNA plasmid vaccine, but early results showed it to be only moderately immunogenic.

src: guardian.ng

Manufacturer in India and Vietnam

Panacea Biotec and Biological E. Limited have vaccine candidates in the earliest stages of development. A company in Vietnam (VABIOTECH) is conducting safety tests and developing a clinical trial plan. All three companies are involved in studies of a TetraVax-DV vaccine in conjunction with the National Institutes of Health.

src: www.medindia.net

References

src: 3.bp.blogspot.com

External links

• Dengue vaccine research. World Health Organization
• Dengue Vaccine Initiative

Source of the article : Wikipedia